Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer - Wikidata - wikimedia - TriplyDB

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

http://www.wikidata.org/entity/Q26829939

about

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies.Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.Clinical significance of post-progression survival in lung cancer Surrogate endpoints for overall survival in lung cancer trials: a review.Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression.Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.

P2860

Q27852105-6BFA5999-B5E7-4EC8-8024-B084369C910E Q30833179-DE6632F5-F670-40E7-9FCD-97DAC6905014 Q33933021-E11D96FB-1AAB-4807-9034-0CE80B4DEF3F Q34866341-588E45B5-5115-462E-A2AB-9694EC92EAA3 Q35164187-AE5483A4-AC65-42E0-AF61-3FBF907FF567 Q36490413-1E0048D2-4BF6-46E2-B8AD-45464843DE20 Q37329579-0D9D0EB1-B76D-4F11-BF31-74A760CD0EFC Q37389608-76ABD24A-FA7E-4C7C-A1FF-E81035F1A5D3 Q37698439-2261ED09-B804-45A4-A485-205E3B02A871 Q37706099-6C046DB9-BBF9-4EF7-9556-C2D179F498E3 Q38062018-B450DDC9-54C2-4274-84EE-66E2FACEC27A Q38133562-F5478032-6FF2-4542-930F-2BB38E59A07F Q38390009-91FD9152-16F4-41BC-9398-00FBEA23DDF8 Q38636718-FF654CEC-F8D3-4937-A270-B2CE380D707D Q38669447-53304920-BB22-4B82-AB56-3CA201F28691 Q38841987-5905DC2A-3B32-443B-B1A3-90B8E4DDB485 Q38852314-75D824B8-F6CB-4071-A57B-9F85583F6141 Q39150005-E3B32C04-5A53-4161-9E6F-914520D90F39 Q39572955-7A8F0F5B-1A5E-4ABF-AAA0-2502FF91FF03 Q40461237-01564CA2-CCB9-498D-AB7D-22BFBCBCB775 Q40955279-6AFF23ED-20AE-4C52-87E8-4AF8CC9AEF80 Q43654035-145E91F2-DE15-480F-BB6E-700BB1AD7DC9 Q44365458-3B7C6396-E259-41A8-88B7-82F14E2FDA84 Q47189344-C2F30AC7-EA4F-4853-9E48-F71706ACFB7B Q50632474-690961A5-A740-46FE-95A2-8538B06CCBEB Q50877426-A88AC11B-5A40-4C21-9DDF-09BE9FBA2DCC Q51088833-34F5D5B2-D6BA-4207-83E9-634A7B9A040B Q53717818-C6FBB8D5-61A4-49D5-BCD0-4A45386C0E80 Q54951150-0F67D40C-E8AC-4C4A-87AB-B0530FEB5364

P2860

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

http://www.wikidata.org/entity/Q26829939

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Postprogression survival for f ...... ced non-small-cell lung cancer

@ast

Postprogression survival for f ...... ced non-small-cell lung cancer

@en

Postprogression survival for f ...... ced non-small-cell lung cancer

@nl

type

label

Postprogression survival for f ...... ced non-small-cell lung cancer

@ast

Postprogression survival for f ...... ced non-small-cell lung cancer

@en

Postprogression survival for f ...... ced non-small-cell lung cancer

@nl

prefLabel

Postprogression survival for f ...... ced non-small-cell lung cancer

@ast

Postprogression survival for f ...... ced non-small-cell lung cancer

@en

Postprogression survival for f ...... ced non-small-cell lung cancer

@nl

P1433

Q26829939-88711D58-15D6-4D7E-98A6-2A261D94A5E5

P1476

Q26829939-7002005E-7B90-44A5-861F-A842F72E8849

P2093

Q26829939-89ED5FB6-2FCA-4147-BC0A-B064956C5F57

Q26829939-8C61F463-E985-4B53-8E5E-F3B7B503788F

Q26829939-A0541F7E-3C87-4F8E-B9D9-59B2F1286C5A

Q26829939-BED2B3F3-E17E-4808-A090-1811B5843826

Q26829939-D12FF66C-9DCD-410D-899C-2DDD4ABF43E8

P2860

Q26829939-06076A35-051D-4D7A-A169-B99B8260EC47

Q26829939-11959492-C9BA-4F7E-AD89-B136FA7FD8F9

Q26829939-4351781E-2DC4-4D95-8F33-FB9F95AC23D3

Q26829939-4CA3D657-D119-4149-8424-532634648198

Q26829939-514DCF31-2B60-45DB-A54F-939F1C5CDB76

Q26829939-5EA0A8E3-DA86-480E-80B7-88DD12AAFD57

Q26829939-6D774FE9-04DD-4372-A089-3830F04C050D

Q26829939-71CC0ED9-5288-49AF-A725-20F4EB3A729B

Q26829939-828D02A8-2D75-4356-8E64-2BEBF897F23E

Q26829939-997F8E83-4214-4DF5-9579-FA061C637282

P304

Q26829939-F209FDFD-7845-4C39-963C-AD2B6CA662DE

P31

Q26829939-EEE6E6A7-858A-40BB-BFBC-77C8B35D9BA3

P3181

Q26829939-1D0D32D8-19D1-4F94-9FD4-0C312F0EC60F

P356

Q26829939-70A40226-8E13-4A1C-8251-EDF6CFF8D35A

P407

Q26829939-2D9C5D2A-3327-4B58-8BDB-F33EA02F4525

P433

Q26829939-32A73278-D7E6-42E0-8655-4CBAE0D804A3

P478

Q26829939-143D85A2-C64E-4AB8-A458-7D606FC12A48

P577

Q26829939-F0DC52D0-92A1-41C9-965A-FD43AAB8C7B3

P698

Q26829939-73A7DA06-E765-4335-B910-FE5DF9ADB702

P921

Q26829939-F1831903-3193-40B3-889F-667D5A67D1E2

P3181

P356

P1433

Annals of Oncology

P1476

Postprogression survival for f ...... ced non-small-cell lung cancer

@en

P2093

H. Hayashi

http://www.w3.org/2001/XMLSchema#string

I. Okamoto

http://www.w3.org/2001/XMLSchema#string

K. Nakagawa

http://www.w3.org/2001/XMLSchema#string

M. Taguri

http://www.w3.org/2001/XMLSchema#string

S. Morita

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis in clinical trials

Erlotinib in previously treated non-small-cell lung cancer

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

Detecting an overall survival benefit that is derived from progression-free survival

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

P304

1537-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

421725

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/ANNONC/MDR487

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22039091

http://www.w3.org/2001/XMLSchema#string

P921